TLI & ATG for Non-Myeloablative Allogeneic Transplantation for MDS and MPD

PHASE2CompletedINTERVENTIONAL
Enrollment

77

Participants

Timeline

Start Date

July 31, 2004

Primary Completion Date

April 30, 2014

Study Completion Date

February 28, 2015

Conditions
Myeloproliferative DisordersBlood CancerMyelodysplastic Syndromes
Interventions
PROCEDURE

Total Lymphoid Irradiation (TLI)

TLI is administered ten times in 120cGy fractions on day -11 through day -7 and day -4 through day -1

PROCEDURE

Anti-Thymocyte Globulin as Conditioning (ATG)

Thymoglobulin will be administered five times intravenously at 1.5 mg/kg/day from day -11 through day -7 for a total dose of 7.5 mg/kg. Thymoglobulin doses will be based on the adjusted ideal body weight if the patient is greater than or equal to 15 kg over ideal body weight.

Trial Locations (1)

94305

Stanford University School of Medicine, Stanford

All Listed Sponsors
collaborator

National Institutes of Health (NIH)

NIH

lead

Stanford University

OTHER

NCT00185796 - TLI & ATG for Non-Myeloablative Allogeneic Transplantation for MDS and MPD | Biotech Hunter | Biotech Hunter